Patients using C Condylox® Gel 0.5% should receive the following information and instructions. This information is intended to aid in the safe and effective use of this medication. It is not intended to disclose all possible adverse or intended effects.
1) This medication should be used only as directed by the health care provider. Patients should be instructed to wash their hands thor-oughly before and after each application. It is for external use only. Avoid contact with the eyes.
2) Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
3) Patients should report any signs of adverse reactions to the health care provider.
4) If no improvement is observed after 4 weeks of treatment, discontinue the medication and consult the health care provider.
Patients should report any signs of adverse reactions to the health care provider.
Carcinogenesis, Mutagenesis and Impairment of Fertility
An 80-week carcinogenicity study in the mouse was performed using a 0.5% podofilox solution applied dermally at 0.04, 0.2 and 1.0 mg/kg/day. There were no differences between the podofilox treated mice at any dose level and vehicle control in the incidence of neoplasia. Published animal studies, in general, have not shown the drug substance, podofilox, to be carcinogenic.2,3,4,5,6 There are published reports that, in mouse studies, crude podophyllin resin (containing podofilox) applied topically to the cervix produced changes resembling carcinoma in situ.7 These changes were reversible at five weeks after cessation of treatment. In one reported experiment, epidermal carcinoma of the vagina and cervix was found in 1 out of 18 mice after 120 applications of podophyllina (the drug was applied twice weekly over a 15-month period).
Podofilox was not mutagenic in the Ames plate reverse mutation assay at concentrations up to 5mg/plate, with and without metabolic activation. No cell transformation related to potential oncogenicity was observed in BALB/3T3 cells after exposure to podofilox at concentrations up to 0. 008ug/mL, without metabolic activation and 12ug/mL podofilox with metabolic activation. Results from the mouse micronucleus in vivo assay using podofilox 0.5% solution at doses up to 25 mg/ kg (75 mg/m2 ) , indicate that podofilox should be considered a potential clastogen (a chemical that induces disruption and breakage of chromosomes).
Daily topical application of 0.5% podofilox solution at doses up to the equivalent of 0.2mg/kg (1.18 mg/m2 , approximately equivalent to the human daily dose) to rats throughout gametogenesis, mating, gestation, parturition and lactation for two generations demonstrated no impairment of fertility.
Pregnancy
Pregnancy Category C: 0.5% podofilox solution was not teratogenic in the rabbit following topical application of up to 0.21 mg/ kg (2.85 mg/m2, approximately 2 times the maximum human dose) once daily for 13 days. The scientific literature contains references that podofilox is embryotoxic in rats when administered intraperitoneally at a dose of 5mg/kg (29.5 mg/m2, approximately 19 times the recommended maximum human dose).9 Teratogenicity and embryotoxicity have not been studied with intravaginal application. Many antimitotic drug products are known to be embryotoxic. There are no adequate and well-controlled studies in pregnant women. Condylox® Gel 0.5% should be used during pregnancy only if the potential benefit Justifies the potential risk to the fetus.
Nursing Mothers
It is not known whether this drug is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from podofilox, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established.
Condylox to understand an ancient culture that had an appreciation of the beautiful yet have had so much horror in its heart?
CORONA, Calif., March 17, 1997 -- The U.S. Food and Drug Administration (FDA) has approved to market Condylox(R) Gel 0.5% (podofilox) for the treatment of external genital and perianal warts (condyloma acuminata). The product is expected to be launched in the second quarter of fiscal 1997.
It is believed that Condylox(R) Gel offers two important advancements over Condylox topical solution, introducedin 1991: easy, finger-tip application and an expanded perianal wart indication.
Oclassen Pharmaceuticals, Inc., a wholly-owned subsidiary of Watson Pharmaceuticals, is dedicated to the development and acquisition of unique proprietary dermatological products.
Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is engaged in the manufacture and sale of off-patent medications and branded pharmaceutical products.
Some more good links:
Auto
immune disease
Disease
Immune system
supplement
Immune stimulator
Immune
AIDS
Immune system
Herpes
Immune disorder
Genital warts
Antioxidant
Wrinkle
Fountain of Youth
Collagen
beauty product
Skin care
Skin Care Product
Anti-aging
Anti aging
Nails
retinol
Hair
skin care
Complex-C
Scar
Wrinkle
Scar removal
Wrinkle cream
Acne scar
Anti-aging
Acne scarring
retinol
Scar treatment
Skin care
Acne Spot Dry
acne
acne cure
acne treatment
acne product
adult acne
acne rosacea
acne medication
acne medicine
cystic acne
acne prevention
AcneVention
Acne
Acne cure
Acne treatment
Acne product
Adult acne
Acne rosacea
Acne medication
Acne
medicine
Cystic
acne
Acne prevention
SkinVantage
Skin care
Anti aging product
Beauty product
Natural skin care
Nails
Healthy skin
Acne treatment
Anti aging
Hair
Skin care product
Kontrole
Immune
AIDS
immune system
Herpes
immune disorder
Genital warts
auto immune disease
disease
immune system supplement
immune stimulator
Anthrax
Herpasil
Herpes
Herpes symptom
Genital herpes
Genital herpes picture
Herpes picture
Picture of herpes
Herpes Zoster
Herpes cure
Herpes simplex
Herpes treatment
HSV
Scar-Wrinkle
scar
wrinkle
Scar removal
Scar Remover
Wrinkle cream
Acne scar
Wrinkle treatment
Scar tissue
Anti aging
AntiAging
Antiaging
Age
scar treatment
skin care
Amazing Breast
Breasts
breast enhancement
breast enlargement
breast enhancer
breast form
breast augmentation
breast surgery
bigger breast
natural breast
enhancement
natural breast
enlargement
Condysil
Genital wart
Hpv virus
Genital wart picture
Genital wart treatment
wart
Human papilloma virus
Condyloma
Sexually transmitted disease
STD
HPV
Acnesil
Acne
Acne cure
Acne treatment
Acne product
Acne medication
Acne scar
Cystic acne
Adult acne
Acne rosacea
Acne medicine
Condysil Gel
Genital wart
Hpv
virus
Genital wart picture
Genital wart treatment
wart
Human papilloma virus
Condyloma
Sexually
transmitted disease
STD
HPV
Condysil Gel
SkinChoice
Stupid-Dick
E-Commerce-Complete
e-commerce
Ecommerce
e commerce
credit card processing
processing
warehousing
submission
site submission
consultants
e-commerce consultants
fulfilment
fufuillment
fufilment
affiliate
affiliate sites
affiliate business
Virtual
Shipping
Shipping
fufuillment
fufilment
warehousing
